ADPT
Adaptive Biotechnologies Corporation$22.59+1.17 (+5.46%)Prev Close$21.43·MCap$3.37B·P/E—·Vol2.59M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
56
$77.55M
◆
Net Activity
Net Seller
$77.55M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Adaptive Biotechnologies Corporation (ADPT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 56 insider sales totaling $77.55M. The most recent insider transaction was by ROBINS HARLAN S (officer: Chief Scientific Officer), who sold $8.50M worth of shares on Jul 7, 2026. Adaptive Biotechnologies Corporation operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $3.37B.
ADPT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 386,240 | $22.01 | $8.50M | 1,166,547 |
| Jul 6, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 95,842 | $22.51 | $2.16M | 279,949-26% |
| Jul 6, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 487 | $22.00 | $10.7K | 406,288 |
| Jun 30, 2026 | BENZENO SHARON | officer: Chief Commercial Ofc Imm Med | Sell | 165,802 | $21.13 | $3.50M | 272,751-38% |
| Jun 29, 2026 | GRIFFIN MICHELLE RENEE | director | Sell | 52,084 | $20.18 | $1.05M | 15,625-77% |
| Jun 29, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 5,000 | $20.50 | $102.5K | 406,775 |
| Jun 17, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 106,160 | $17.41 | $1.85M | 1,412,058 |
| Jun 15, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 5,000 | $19.00 | $95.0K | 411,775 |
| Jun 8, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 39,741 | $17.49 | $695.1K | 250,934 |
| Jun 8, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 11,000 | $18.00 | $198.0K | 416,775 |
| May 20, 2026 | PISKEL KYLE | officer: Chief Financial Officer | Sell | 3,115 | $13.04 | $40.6K | 256,725 |
| Apr 29, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 19,037 | $14.23 | $270.9K | 377,802 |
| Apr 24, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.96 | $798.4K | 390,808 |
| Apr 21, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 69,061 | $14.60 | $1.01M | 403,822 |
| Apr 16, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $14.45 | $826.3K | 416,836 |
| Apr 13, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.26 | $758.1K | 431,950 |
| Apr 10, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 22,564 | $15.07 | $340.0K | 271,154 |
| Apr 10, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 10,000 | $14.85 | $148.5K | 1,512,058 |
| Apr 8, 2026 | ROBINS CHAD M | director, officer: CEO and Chairman | Sell | 120,595 | $14.65 | $1.77M | 2,217,781 |
| Apr 8, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 69,061 | $14.34 | $990.5K | 442,864 |
| Apr 2, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 38,120 | $14.53 | $553.7K | 451,540 |
| Mar 31, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.14 | $751.3K | 480,876 |
| Mar 26, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $14.03 | $802.2K | 477,568 |
| Mar 23, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.46 | $769.6K | 490,582 |
| Mar 18, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.33 | $762.2K | 503,596 |
| Mar 13, 2026 | BENZENO SHARON | officer: Chief Commercial Ofc Imm Med | Sell | 63,103 | $13.17 | $831.1K | 272,751 |
| Mar 13, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 41,338 | $13.17 | $544.4K | 427,775 |
| Mar 13, 2026 | GRIFFIN MICHELLE RENEE | director | Sell | 15,394 | $13.91 | $214.1K | 15,625-50% |
| Mar 13, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 30,593 | $14.08 | $430.7K | 291,374 |
| Mar 13, 2026 | PISKEL KYLE | officer: Chief Financial Officer | Sell | 18,672 | $13.17 | $245.9K | 259,840 |
| Mar 13, 2026 | ROBINS CHAD M | director, officer: CEO and Chairman | Sell | 470,167 | $13.17 | $6.19M | 2,630,713 |
| Mar 13, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 470,266 | $13.17 | $6.19M | 1,851,658 |
| Mar 13, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 179,703 | $13.21 | $2.37M | 520,948-26% |
| Mar 10, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 81,342 | $14.90 | $1.21M | 652,147 |
| Mar 9, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 38,074 | $15.09 | $574.5K | 321,967 |
| Mar 5, 2026 | GRIFFIN MICHELLE RENEE | director | Sell | 48,044 | $15.30 | $735.1K | 15,394-76% |
| Mar 5, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 92,823 | $16.09 | $1.49M | 590,429 |
| Feb 4, 2026 | PISKEL KYLE | Chief Financial Officer | Sell | 2,145 | $18.46 | $39.6K | 0 |
| Feb 2, 2026 | ROBINS CHAD M | CEO and Chairman | Sell | 124,998 | $18.44 | $2.30M | 0 |
| Feb 2, 2026 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 42,788 | $18.68 | $799.1K | 0 |
| Jan 12, 2026 | LO FRANCIS | Chief People Officer | Sell | 79,590 | $17.73 | $1.41M | 0 |
| Jan 12, 2026 | PISKEL KYLE | Chief Financial Officer | Sell | 4,290 | $18.00 | $77.2K | 0 |
| Jan 6, 2026 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 10,000 | $16.44 | $164.4K | 0 |
| Jan 5, 2026 | ROBINS CHAD M | CEO and Chairman | Sell | 124,998 | $15.59 | $1.95M | 0 |
| Jan 2, 2026 | LO FRANCIS | Chief People Officer | Sell | 3,125 | $16.08 | $50.3K | 0 |
| Dec 22, 2025 | LO FRANCIS | Chief People Officer | Sell | 4,394 | $17.50 | $76.9K | 0 |
| Dec 15, 2025 | LO FRANCIS | Chief People Officer | Sell | 113,890 | $15.57 | $1.77M | 0 |
| Dec 10, 2025 | HERSHBERG ROBERT | Director | Sell | 22,968 | $16.00 | $367.5K | 0 |
| Dec 4, 2025 | BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell | 12,604 | $16.85 | $212.4K | 0 |
| Dec 3, 2025 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 37,212 | $18.07 | $672.5K | 0 |
Showing 1–50 of 182
1 / 4
ADPT Insider Buying Activity
The following table shows recent insider purchases of Adaptive Biotechnologies Corporation (ADPT) stock reported via SEC Form 4 filings.
No insider buying activity found for ADPT in the last 12 months.
ADPT Insider Selling Activity
The following table shows recent insider sales of Adaptive Biotechnologies Corporation (ADPT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 386,240 | $22.01 | $8.50M | 1,166,547 |
| Jul 6, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 95,842 | $22.51 | $2.16M | 279,949-26% |
| Jul 6, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 487 | $22.00 | $10.7K | 406,288 |
| Jun 30, 2026 | BENZENO SHARON | officer: Chief Commercial Ofc Imm Med | Sell | 165,802 | $21.13 | $3.50M | 272,751-38% |
| Jun 29, 2026 | GRIFFIN MICHELLE RENEE | director | Sell | 52,084 | $20.18 | $1.05M | 15,625-77% |
| Jun 29, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 5,000 | $20.50 | $102.5K | 406,775 |
| Jun 17, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 106,160 | $17.41 | $1.85M | 1,412,058 |
| Jun 15, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 5,000 | $19.00 | $95.0K | 411,775 |
| Jun 8, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 39,741 | $17.49 | $695.1K | 250,934 |
| Jun 8, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 11,000 | $18.00 | $198.0K | 416,775 |
| May 20, 2026 | PISKEL KYLE | officer: Chief Financial Officer | Sell | 3,115 | $13.04 | $40.6K | 256,725 |
| Apr 29, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 19,037 | $14.23 | $270.9K | 377,802 |
| Apr 24, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.96 | $798.4K | 390,808 |
| Apr 21, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 69,061 | $14.60 | $1.01M | 403,822 |
| Apr 16, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $14.45 | $826.3K | 416,836 |
| Apr 13, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.26 | $758.1K | 431,950 |
| Apr 10, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 22,564 | $15.07 | $340.0K | 271,154 |
| Apr 10, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 10,000 | $14.85 | $148.5K | 1,512,058 |
| Apr 8, 2026 | ROBINS CHAD M | director, officer: CEO and Chairman | Sell | 120,595 | $14.65 | $1.77M | 2,217,781 |
| Apr 8, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 69,061 | $14.34 | $990.5K | 442,864 |
| Apr 2, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 38,120 | $14.53 | $553.7K | 451,540 |
| Mar 31, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.14 | $751.3K | 480,876 |
| Mar 26, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $14.03 | $802.2K | 477,568 |
| Mar 23, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.46 | $769.6K | 490,582 |
| Mar 18, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.33 | $762.2K | 503,596 |
| Mar 13, 2026 | BENZENO SHARON | officer: Chief Commercial Ofc Imm Med | Sell | 63,103 | $13.17 | $831.1K | 272,751 |
| Mar 13, 2026 | BOBULSKY SUSAN | officer: Chief Commercial Officer, MRD | Sell | 41,338 | $13.17 | $544.4K | 427,775 |
| Mar 13, 2026 | GRIFFIN MICHELLE RENEE | director | Sell | 15,394 | $13.91 | $214.1K | 15,625-50% |
| Mar 13, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 30,593 | $14.08 | $430.7K | 291,374 |
| Mar 13, 2026 | PISKEL KYLE | officer: Chief Financial Officer | Sell | 18,672 | $13.17 | $245.9K | 259,840 |
| Mar 13, 2026 | ROBINS CHAD M | director, officer: CEO and Chairman | Sell | 470,167 | $13.17 | $6.19M | 2,630,713 |
| Mar 13, 2026 | ROBINS HARLAN S | officer: Chief Scientific Officer | Sell | 470,266 | $13.17 | $6.19M | 1,851,658 |
| Mar 13, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 179,703 | $13.21 | $2.37M | 520,948-26% |
| Mar 10, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 81,342 | $14.90 | $1.21M | 652,147 |
| Mar 9, 2026 | LO FRANCIS | officer: Chief People Officer | Sell | 38,074 | $15.09 | $574.5K | 321,967 |
| Mar 5, 2026 | GRIFFIN MICHELLE RENEE | director | Sell | 48,044 | $15.30 | $735.1K | 15,394-76% |
| Mar 5, 2026 | RUBINSTEIN JULIE | officer: President and COO | Sell | 92,823 | $16.09 | $1.49M | 590,429 |
| Feb 4, 2026 | PISKEL KYLE | Chief Financial Officer | Sell | 2,145 | $18.46 | $39.6K | 0 |
| Feb 2, 2026 | ROBINS CHAD M | CEO and Chairman | Sell | 124,998 | $18.44 | $2.30M | 0 |
| Feb 2, 2026 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 42,788 | $18.68 | $799.1K | 0 |
| Jan 12, 2026 | LO FRANCIS | Chief People Officer | Sell | 79,590 | $17.73 | $1.41M | 0 |
| Jan 12, 2026 | PISKEL KYLE | Chief Financial Officer | Sell | 4,290 | $18.00 | $77.2K | 0 |
| Jan 6, 2026 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 10,000 | $16.44 | $164.4K | 0 |
| Jan 5, 2026 | ROBINS CHAD M | CEO and Chairman | Sell | 124,998 | $15.59 | $1.95M | 0 |
| Jan 2, 2026 | LO FRANCIS | Chief People Officer | Sell | 3,125 | $16.08 | $50.3K | 0 |
| Dec 22, 2025 | LO FRANCIS | Chief People Officer | Sell | 4,394 | $17.50 | $76.9K | 0 |
| Dec 15, 2025 | LO FRANCIS | Chief People Officer | Sell | 113,890 | $15.57 | $1.77M | 0 |
| Dec 10, 2025 | HERSHBERG ROBERT | Director | Sell | 22,968 | $16.00 | $367.5K | 0 |
| Dec 4, 2025 | BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell | 12,604 | $16.85 | $212.4K | 0 |
| Dec 3, 2025 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 37,212 | $18.07 | $672.5K | 0 |
ADPT Insiders
Similar Stocks to ADPT
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B